Incretin Tolerability Endpoints in Canada: A Research Guide to Nausea Signals, Gastric Emptying, Satiety, Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide

Why incretin tolerability needed its own weight-management guide#

Northern Compound already covers GLP-1 receptor peptide research, GIP receptor peptides, glucagon receptor co-agonist research, amylin pathway peptides, gastric-emptying peptide research, incretin receptor desensitization, incretin peptide stability, and direct Semaglutide vs Tirzepatide comparison. Those pages explain receptor biology and weight-management endpoint logic. What was still missing was a tolerability-first guide: how should Canadian readers interpret incretin and amylin-adjacent peptide claims when reduced intake, slower gastric emptying, visceral malaise, and nausea-like endpoints may all look similar from a distance?

That gap matters because tolerability can change the meaning of a weight-management result. If a model eats less after a GLP-1 receptor agonist, that may reflect satiety signalling. It may also reflect delayed gastric emptying, conditioned aversion, malaise, stress, dehydration, altered palatability, or general sickness behaviour. If a protocol only reports body weight or food intake, the reader cannot tell which layer moved. The claim becomes too broad.

The same problem appears in product comparison content. Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide sit in related but different pharmacology lanes. GLP-1, GIP, glucagon, and amylin systems can each influence appetite, energy expenditure, glucose handling, gastric motility, visceral sensation, and meal patterning. A useful article does not rank them with a single slogan. It asks which tolerability endpoints were measured and whether the outcome could be explained without invoking clean fat-loss biology.

This guide is written for Canadian readers evaluating non-clinical, research-use-only materials, endpoint design, supplier documentation, and evidence language. It does not provide medical advice, adverse-event advice, weight-loss guidance, gastrointestinal guidance, dosing, titration, route selection, compounding instructions, or personal-use recommendations. Clinical and adverse-event terms appear because incretin literature often reports them; Northern Compound's frame here is research interpretation and RUO sourcing discipline.

The short answer: do not mistake malaise for satiety#

A defensible incretin-tolerability project starts by separating three layers: appetite and satiety signalling, gastrointestinal motility, and aversive or malaise-like responses. Those layers can overlap, but they are not interchangeable. Reduced food intake is an output, not a mechanism.

Within the current Northern Compound product map, Semaglutide is the cleanest GLP-1 receptor reference when the research question centres on GLP-1R-mediated appetite, glucose, gastric-emptying, or nausea-like endpoints. Tirzepatide is relevant when dual GIPR/GLP-1R pharmacology could change efficacy or tolerability interpretation. Retatrutide belongs when GLP-1/GIP/glucagon tri-agonist biology, energy expenditure, and gastrointestinal signals are all part of the model. Cagrilintide is the amylin-pathway reference when satiety, meal size, gastric-emptying context, and aversion controls are central.

Those links are documentation checkpoints for research-use-only materials. They are not evidence that any compound is appropriate for personal weight loss, treats obesity, manages appetite, prevents nausea, improves metabolic health, or belongs in a dosing protocol.

Incretin tolerability biology in one cautious map#

GLP-1 is an incretin hormone with effects on insulin secretion, glucagon suppression, gastric emptying, appetite circuits, and brainstem-hypothalamic signalling. Long-acting GLP-1 receptor agonists are discussed extensively in metabolic literature, including regulated clinical settings, but RUO content has to translate that literature carefully. A clinical adverse-event table does not become instructions for personal use. It becomes context for which endpoints a non-clinical model should measure.

GLP-1 receptor activation can reduce food intake through central and peripheral pathways. It can also delay gastric emptying. The nucleus tractus solitarius, area postrema, vagal afferents, hypothalamic circuits, and gastrointestinal feedback loops all matter. Reviews of GLP-1 biology describe a distributed gut-brain-metabolic system rather than a single appetite switch (PMID: 32768375; PMID: 30280673).

GIP biology complicates the story. GIP receptor signalling interacts with insulin secretion, adipose biology, and central pathways, and dual agonists can produce different profiles from selective GLP-1R agonism. Glucagon receptor activity adds another layer by influencing hepatic glucose output, energy expenditure, amino-acid metabolism, and thermogenic context. Amylin and calcitonin-receptor-family pathways can affect satiation, gastric emptying, and area-postrema signalling. This is why a tri-agonist, a dual agonist, a GLP-1 agonist, and an amylin analogue should not be reduced to one shared phrase like appetite peptide.

Tolerability is the practical bridge between mechanism and interpretation. A compound can look more potent because it produces stronger satiety. It can also look more potent because it produces stronger aversive signalling. In human trials, nausea, vomiting, diarrhoea, constipation, dyspepsia, and other gastrointestinal adverse events are reported directly. In animal studies, the signal has to be inferred through imperfect proxies. In cell studies, tolerability may not be testable at all. Each model therefore carries a claim boundary.

Semaglutide: GLP-1R results need gastric and aversion controls#

Semaglutide is a long-acting GLP-1 receptor agonist and the clearest single-receptor anchor for incretin tolerability discussions. Northern Compound already covers it in the Semaglutide Canada guide, GLP-1 receptor peptide guide, gastric-emptying guide, and Semaglutide vs Tirzepatide comparison.

In a tolerability-first research design, Semaglutide is useful because GLP-1R activation sits close to both efficacy and gastrointestinal signals. A protocol measuring food intake should ask whether intake fell through smaller meals, fewer meals, delayed first meal, increased inter-meal interval, altered food preference, or aversion. A protocol measuring body weight should pair that with intake, hydration, lean and fat mass, activity, glucose, insulin, and ideally energy-expenditure context.

Gastric emptying is especially easy to overread. GLP-1R agonists can slow gastric emptying, but the magnitude and timing may change with exposure, species, meal composition, baseline glucose state, and adaptation. A delayed-emptying result may explain early intake suppression or glucose excursion changes, but it should not be treated as the whole mechanism without central appetite and aversion controls. Conversely, reduced gastric-emptying effect over time does not prove central appetite signalling disappeared.

For Canadian RUO sourcing, Semaglutide material should be evaluated by exact identity, sequence or analogue clarity, lot-specific HPLC purity, identity confirmation, fill amount, batch number, storage conditions, and research-use-only labelling. Because incretin materials can be sensitive to handling and concentration error, the article should not interpret subtle food-intake or gastric endpoints from unverifiable material.

Tirzepatide: dual agonism changes the interpretation problem#

Tirzepatide is usually discussed as a dual GIPR/GLP-1R agonist. The dual framing matters because a Tirzepatide result cannot be treated as GLP-1R biology with a larger number attached. GIPR engagement may alter insulin secretion, adipose signalling, central response, nausea-like adaptation, and metabolic context. Northern Compound covers that receptor layer in GIP receptor peptides and the direct Semaglutide vs Tirzepatide comparison.

A tolerability-first Tirzepatide design should measure the same core outputs as a GLP-1R study while adding receptor-specific caution. If the protocol finds lower intake, is the meal-pattern change similar to a GLP-1R-only comparator or different? If body weight changes, is the effect explained by lower intake, altered energy expenditure, improved glucose handling, reduced fat mass, lean-mass change, or illness-like behaviour? If gastric emptying changes less or more than expected, does the design include enough timing to separate acute and repeated-exposure effects?

The marketing error is to describe dual agonism as automatically better tolerated or automatically more powerful. That may be true in a specific design, but it must be shown by endpoints. A dual agonist can have different tolerability, but the claim needs a denominator: compared with what receptor exposure, what time point, what species, what dose range, what meal pattern, what adverse-signal proxy, and what material quality?

Material documentation has the same burden: exact peptide identity, lot-specific purity, identity confirmation, fill amount, storage, RUO labelling, and vehicle controls. Dual agonism makes the biology more interesting, not less dependent on clean input material.

Retatrutide: tri-agonist claims need energy-expenditure and GI separation#

Retatrutide is discussed as a GLP-1/GIP/glucagon receptor tri-agonist. The glucagon receptor layer changes the research question because glucagon biology can influence hepatic glucose output, amino-acid metabolism, energy expenditure, and possibly body-composition interpretation. Northern Compound covers this broader lane in glucagon receptor co-agonist peptide research, adipose thermogenesis, and hepatic lipid peptide research.

A tri-agonist tolerability design should not use weight change as a catch-all. If the model loses weight, the protocol should ask how much came from lower intake, how much from altered energy expenditure, how much from fluid or gastrointestinal change, and whether lean mass was protected. Food intake, indirect calorimetry, body composition, activity, temperature, glucose, insulin, liver markers, ketone or substrate context where relevant, and gastrointestinal endpoints are all more useful than a single scale value.

The tolerability layer is important because glucagon-adjacent pharmacology can make interpretation noisy. Higher energy expenditure or altered substrate use may coexist with appetite suppression, gastric effects, nausea-like behaviour, or stress responses. If the design does not measure aversion and gut transit, it cannot cleanly say whether the tri-agonist profile improved metabolic efficiency or simply reduced intake through unpleasant signals.

For RUO readers, Retatrutide sourcing should be treated as high documentation burden. Multi-receptor peptides require exact identity language, purity and identity confirmation, storage and stability awareness, and careful avoidance of clinical outcome language. A tracked ProductLink is a way to inspect documentation, not a recommendation.

Cagrilintide: amylin-pathway satiety must be separated from aversion#

Cagrilintide is an amylin analogue discussed around satiation, meal size, gastric-emptying context, and area-postrema or brainstem signalling. It belongs in this tolerability article because amylin-pathway research sits directly on the boundary between satiety and nausea-like interpretation. Northern Compound covers the receptor lane in amylin pathway peptide research and the broader weight-management map in central appetite circuitry.

A Cagrilintide study that reports lower intake should show whether meal size changed, whether meal frequency changed, whether food preference shifted, whether gastric emptying or gut transit changed, and whether aversion proxies were checked. Amylin-related pathways can engage brainstem circuits that overlap with visceral feedback. That does not make every amylin-pathway signal aversive, but it does mean the protocol should not assume clean satiety from intake alone.

Combination designs raise the bar further. If an amylin analogue is studied alongside a GLP-1R or dual incretin compound, the result can reflect additive satiety, complementary receptor biology, delayed gastric emptying, aversion, altered meal patterning, or general reduced activity. A useful article names the layer. It does not call every combination synergistic unless the endpoint design can support synergy rather than simple summed intolerance.

What to measure before making a tolerability claim#

Meal patterning rather than only daily intake#

Daily food intake is a blunt instrument. Meal size, meal frequency, first-meal latency, inter-meal interval, nocturnal versus light-phase intake, preference shifts, and water intake give a much cleaner picture. A compound that reduces first-meal size may be acting differently from one that delays all feeding or disrupts normal rhythm. If a study reports only 24-hour intake, the conclusion should be modest.

Gastric emptying and gut transit#

Gastric-emptying tests should match the model. Acetaminophen absorption is used as a proxy in some contexts, labelled meals can be used in others, and rodent bead or marker transit can answer different gut-motility questions. Meal composition, glucose state, stress, anaesthesia, acclimation, and timing can all change the result. A delayed-emptying signal is mechanistically useful only when it is paired with food-intake, glucose, and aversion context.

Nausea-like and aversion proxies#

Animals cannot simply report nausea. Researchers often use conditioned taste avoidance, pica or kaolin intake in rodents, gaping responses in species where validated, activity suppression, posture, grooming, hydration, and behaviour scoring. Each proxy is imperfect. Conditioned taste avoidance can reflect learning and aversion without direct equivalence to human nausea. Pica is species- and protocol-dependent. Locomotor suppression can reflect malaise, sedation, stress, or unrelated motor effects. The answer is not to avoid these measures; it is to interpret them as a panel.

Hydration, stool, and general health context#

Gastrointestinal tolerability can affect hydration, stool output, transit time, and general activity. If a model reduces intake and weight while also showing dehydration, abnormal stool, low activity, or stress markers, the metabolic interpretation weakens. A body-weight change under those conditions should not be described as clean fat-mass biology without body-composition and health-context data.

Glucose and insulin context#

Incretin peptides often affect glucose and insulin endpoints. Those markers can help explain food intake, gastric emptying, and energy balance, but they can also confound interpretation. Hypoglycaemia-like behaviour, altered glucose excursions, insulin sensitivity, and feeding state can change activity and appetite. A tolerability article should report metabolic context alongside behaviour rather than treating them as separate stories.

Body composition and lean-mass preservation#

Weight is not enough. Fat mass, lean mass, tissue water, food intake, activity, and energy expenditure define what a weight-management signal means. Northern Compound's lean-mass preservation guide covers this in more detail. For tolerability work, lean mass matters because excessive intake suppression or malaise-like effects can produce weight change that looks impressive but is not cleanly desirable or mechanistically specific.

Model selection: what each system can prove#

Cell systems can answer receptor, signalling, stability, and potency questions. They cannot answer nausea, satiety, gastric emptying, or tolerability. A cell assay can show receptor activation or signalling bias, but it should not be used to claim that a compound is better tolerated.

Rodent studies can connect meal patterns, body weight, glucose, gastric transit, aversion proxies, and tissue endpoints. They also require care. Rodents do not vomit, so nausea-like interpretation depends on proxies such as pica or conditioned taste avoidance. Light-dark cycles, housing temperature, diet composition, acclimation, stress, sex, age, strain, and prior exposure can all change feeding behaviour.

Larger animal models may offer different gastric and emesis relevance, but they introduce cost, ethics, and species-specific pharmacology. A result in one species does not automatically translate to another because receptor distribution, gastric physiology, and behavioural proxies differ.

Human clinical literature provides direct adverse-event reporting, but it belongs in a different regulatory context. RUO supplier articles can cite it to understand endpoint logic, not to provide use advice. If a clinical trial reports nausea rates, titration schedules, or discontinuation data, Northern Compound should translate that into research questions: what endpoints captured tolerability, what time course mattered, and how did the study separate efficacy from adverse-event burden?

Time course: early tolerability is not the same as sustained metabolic signal#

Incretin and amylin-adjacent research can change meaning across time. The first exposure window may be dominated by gastric-emptying delay, novelty, taste or vehicle effects, conditioned aversion, or acute visceral feedback. A later window may show adaptation, receptor desensitization, changed meal patterning, body-composition effects, or central appetite changes that were not visible early. A single time point is therefore a weak basis for comparing compounds.

A stronger design separates acute, subacute, and longer exposure windows. Acute endpoints might include first-meal latency, meal size, water intake, gastric emptying, glucose excursion, locomotion, and aversion proxies. Subacute endpoints might include repeated meal patterning, body-weight trajectory, stool output, hydration markers, and signs of adaptation. Longer windows should add body composition, energy expenditure, tissue markers, receptor-expression context where relevant, and material-stability records. If the article does not say which window was measured, the reader should assume the conclusion is narrower than the headline.

This time-course issue is especially important when comparing Semaglutide with Tirzepatide, Retatrutide, or Cagrilintide. A compound can look harder to tolerate early and more interpretable later, or the reverse. A compound can show strong first-week intake suppression because of aversion and then weaker sustained metabolic separation after acclimation. Another can show modest early intake change but clearer body-composition or glucose context later. Without time-resolved endpoints, rankings are often just snapshots.

The cautious editorial move is to write the time window into the claim. "Reduced first-day food intake" is not the same as "sustained satiety." "Delayed gastric emptying after acute exposure" is not the same as "long-term appetite control." "Weight change after repeated exposure" is not the same as "good tolerability." These distinctions make the article less flashy and more useful.

Assay and handling issues that can masquerade as tolerability#

Behavioural and gut-motility studies are vulnerable to boring errors. That is exactly why they need to be named. A small concentration mistake can make a compound appear unusually potent or unusually poorly tolerated. A vehicle with unexpected pH, osmolarity, preservative residue, or solvent carryover can change intake. Repeated freeze-thaw cycles can degrade peptide material and produce mixed signals. Poor randomisation, cage-position effects, inadequate acclimation, or measuring intake during the wrong light-dark phase can create false differences.

Food itself is part of the assay. Chow composition, high-fat diet composition, palatability, texture, caloric density, prior diet exposure, fasting duration, and refeeding schedule can all change the response to incretin or amylin-pathway materials. A protocol that uses overnight fasting may amplify first-meal effects compared with ad libitum conditions. A high-fat diet model may respond differently from a chow-fed model. A preference test may detect aversion that a simple intake measurement misses.

Stress is another hidden driver. Handling, injections or mock procedures, restraint, temperature, noise, cage change, single housing, and unfamiliar equipment can all alter feeding and gastrointestinal function. If the compound group experiences more handling stress than controls, the study may measure stress physiology rather than receptor pharmacology. Northern Compound does not provide route guidance, but it does expect any route or handling context in the literature to be treated as an experimental variable, not a lifestyle instruction.

For article quality, the implication is simple: do not over-clean the story. A good tolerability section should mention vehicle controls, acclimation, light-dark timing, diet, hydration, locomotion, randomisation, blinded scoring where possible, and batch documentation. The goal is not to make every reader a technician. The goal is to stop weak content from turning a noisy behaviour signal into a confident product claim.

How to compare compounds without making a fake league table#

Readers often want a ranking: which incretin peptide is strongest, cleanest, or best tolerated? That is the wrong first question. A ranking only makes sense after the endpoint hierarchy is shared. Stronger appetite suppression with more aversion is not necessarily better biology. Less gastric delay with weaker glucose effect may or may not fit the research question. More weight change with more lean-mass loss is not a clean win. Better glucose with unchanged body composition answers a different question than stronger fat-mass loss.

A useful comparison should start with the receptor lane. Semaglutide anchors GLP-1R-focused interpretation. Tirzepatide adds GIPR/GLP-1R dual context. Retatrutide adds glucagon receptor questions around energy expenditure and hepatic metabolism. Cagrilintide adds amylin-pathway satiation and area-postrema context. Those differences make one-compound-fits-all comparisons weak.

Then compare by endpoint. For appetite circuitry, look at meal patterning, hypothalamic and brainstem markers, preference, and aversion controls. For gastrointestinal interpretation, look at gastric emptying, stool output, gut transit, hydration, and timing. For metabolic interpretation, look at glucose, insulin, indirect calorimetry, liver context, body composition, and lean-mass preservation. For tolerability, look at discontinuation or adverse-event reporting in clinical literature only as context, then translate it back into measurable research proxies rather than personal-use advice.

Finally, compare material documentation. A compound with a cleaner receptor story but weaker COA, unclear identity, or questionable storage is not a cleaner research input. Lot-specific documentation is not glamorous, but it is the difference between a biological comparison and a guessing contest.

Canadian compliance framing for incretin content#

Incretin language creates extra compliance risk because the public conversation around these compounds is intensely consumer-facing. Words like weight loss, appetite control, nausea, side effects, and titration can easily drift from evidence interpretation into personal guidance. Northern Compound should not do that. It can discuss those terms as research endpoints, clinical-trial context, or supplier-claim filters. It should not instruct readers on managing effects, selecting products for themselves, changing exposure, escalating dose, combining compounds, or troubleshooting adverse events.

The safer, more useful framing is endpoint-first. Instead of saying a compound is easier on the stomach, say which gastric-emptying, stool, hydration, or aversion endpoints were measured. Instead of saying a compound controls appetite, say whether meal size, frequency, preference, and first-meal latency changed. Instead of saying a compound preserves lean mass, say whether body composition and intake were measured together. Instead of saying a supplier is best, say whether the supplier provides current lot-specific documentation, clear RUO labelling, and product-page availability.

This is not just legal caution. It is better editorial work. Serious readers can tell when an article is trying to smuggle consumer advice through scientific language. The Northern Compound standard is narrower: research-use-only materials, Canadian sourcing discipline, evidence boundaries, and practical endpoint literacy.

Supplier and COA controls for incretin-tolerability research#

Tolerability endpoints are sensitive to material quality. Wrong identity, degradation, concentration error, residual solvent, endotoxin, pH shift, aggregation, storage abuse, vehicle effects, or fill inconsistency can change food intake, behaviour, cytokines, glucose, and gut motility. In an incretin study, those artefacts may look like biology.

For Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide, Canadian readers should inspect:

1. exact compound name and analogue identity;
2. sequence or structural clarity where supplier documentation provides it;
3. lot-specific HPLC purity rather than generic purity language;
4. identity confirmation, ideally mass-based where appropriate;
5. fill amount, batch number, and certificate date;
6. storage conditions and stability notes;
7. vehicle compatibility and concentration-control planning for the research model;
8. endotoxin and microbial-contamination awareness when behaviour, cytokines, gut, or systemic endpoints are central;
9. clear research-use-only labelling without weight-loss, therapeutic, adverse-event, dosing, injection, titration, or personal-use claims;
10. product-page availability so research links do not route to dead pages.

ProductLink references preserve Northern Compound attribution parameters and click-event metadata. That transparency does not validate a supplier lot or a biological claim. It keeps sourcing inspection traceable and avoids raw store URLs.

Red flags in incretin tolerability content#

The first red flag is food intake described as pure satiety. Reduced intake can reflect satiety, delayed gastric emptying, aversion, malaise, dehydration, stress, or altered palatability. The article should say which endpoints separate those possibilities.

The second red flag is weight loss used as a tolerability proof. Weight change does not prove a compound was well tolerated. It can happen because the model ate less for the wrong reason.

The third red flag is receptor-name overconfidence. GLP-1, GIP, glucagon, and amylin biology are useful maps, not guarantees. A receptor label does not replace meal-pattern, gut-motility, aversion, and metabolic endpoints.

The fourth red flag is clinical adverse-event language imported into RUO sourcing. A research article can discuss nausea as an endpoint. It should not give adverse-event management guidance, titration suggestions, or personal-use troubleshooting.

The fifth red flag is weak COA discipline. In a model where behaviour and gut motility can shift subtly, material identity and storage are not administrative details. They are part of the method.

How this guide connects to the weight-management archive#

Use the GLP-1 receptor guide when the primary question is GLP-1R biology. Use the GIP receptor guide when dual agonism and GIPR context matter. Use glucagon receptor co-agonist research when energy expenditure and hepatic context enter the model. Use the amylin pathway guide when satiation, area-postrema signalling, and amylin analogues are central.

Use this tolerability guide when the question is whether the outcome is interpretable at all. Before comparing Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide, ask whether the study separated satiety from malaise and gastric delay from appetite signalling. That filter makes the rest of the archive stronger.

Practical interpretation scenarios#

Scenario one: food intake falls sharply in the first 24 hours#

A sharp early intake drop can be meaningful, but it is not automatically clean satiety. The first questions are meal timing, water intake, locomotion, body temperature, stool output, gastric emptying, and aversion proxies. If those are missing, the strongest statement may be: intake was reduced under this exposure window. That is useful but narrow.

Scenario two: body weight falls while activity also falls#

Lower activity can signal malaise, sedation, stress, altered temperature, or reduced motivation. In that context, body-weight change should not be framed as clean metabolic efficacy. Add body composition, food intake, water intake, indirect calorimetry, glucose, insulin, and behaviour scoring before comparing compounds.

Scenario three: gastric emptying slows but intake still drops later#

Early gastric-emptying delay may explain part of intake suppression, especially soon after exposure. Later intake changes may involve central appetite, learned aversion, adaptation, or other metabolic signals. The article should avoid a single-cause explanation unless the time course supports it.

Scenario four: a dual or tri-agonist looks better than a GLP-1-only comparator#

Better by what endpoint? If the result is body weight alone, the comparison is weak. If the design includes meal patterning, aversion proxies, gastric emptying, glucose, insulin, energy expenditure, body composition, and material controls, the comparison becomes much stronger. Multi-receptor pharmacology deserves multi-layer endpoints.

A stronger endpoint hierarchy for incretin tolerability content#

The weakest evidence is a supplier claim, anecdote, or single body-weight curve. Slightly better is food intake plus body weight. Better again is meal patterning, glucose, insulin, gastric-emptying context, activity, hydration, and body composition. Stronger still is a design that adds aversion proxies, receptor-specific comparators, exposure timing, energy expenditure, tissue endpoints, and lot-specific material verification.

For GLP-1R claims, gastric and aversion controls are close to mandatory. For GIP/GLP-1 dual agonism, the protocol should distinguish receptor contribution rather than assuming the combination explains every outcome. For GLP-1/GIP/glucagon tri-agonism, energy expenditure and hepatic context should be measured instead of inferred. For amylin-pathway claims, meal size and aversion proxies deserve special attention.

That hierarchy is also a content-quality filter. If an article uses phrases like "appetite control," "easy weight loss," "no nausea," "better tolerated," or "metabolic reset" without naming endpoints, it is not doing serious interpretation. If it separates satiety, gastric motility, aversion, metabolic context, and material quality, it is closer to the Northern Compound standard.

References and further reading#

• GLP-1 receptor biology and gut-brain appetite signalling: PMID: 32768375
• GLP-1 pharmacology and metabolic physiology review context: PMID: 30280673
• GIP and GLP-1 receptor agonism review literature: PubMed search
• Glucagon receptor co-agonist and tri-agonist research context: PubMed search
• Amylin, satiation, and area-postrema biology: PubMed search
• Conditioned taste avoidance and nausea-like proxy interpretation: PubMed search
• Gastric-emptying methods in incretin research: PubMed search

FAQ#